Tocilizumab induces significant changes in longitudinal proteomes of blood serum from patients with severe COVID-19 pneumonia
José Cordero, Graciela Bravo, Pedro H. Silva, Benjamin Lozano, Elizabeth Rivas, Valeria Labra, Daniela Villalobos, Pablo Saldivia, Mauricio Hernández, Elard S. Koch, Cristian Vargas, Estefanía Nova-Lamperti, Nelson P. Barrera, Jaime Retamal
This study shows that tocilizumab reduces inflammation in severe COVID-19 by altering serum proteomes, restoring protein levels to healthy states.
bioRxiv · May 6, 2026 · PreprintPharmacology & Toxicology